Clinical trials: Liraglutide
Pre Diabetes, Polycystic Ovary Syndrome
Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS
There is a growing need to develop pharmacologic interventions to improve metabolic function in women with polycystic ovary syndrome (PCOS).
- Conditions
- Pre Diabetes, Polycystic Ovary Syndrome, Obesity Android
- Trial name
- SAXAPCOS (NCT03480022)
- Testing
- Liraglutide Pen Injector [Saxenda]
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Woman's
Obesity
Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in Obesity
This study is being done to assess the stomach emptying effect of a maximum dose of 3 mg Liraglutide compared to placebo in subjects who are overweight or obese.
- Trial name
- NCT03523273
- Testing
- Liraglutide
- Where
- United States
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Michael Camilleri, MD
Diabetes Mellitus, Type 2
Effect of Liraglutide on Vascular Inflammation in Type-2 Diabetes
The objective of this study is to evaluate the mechanism behind the anti-atherogenic effects of liraglutide. In a randomized, placebo-controlled, double-blind, parallel trial we will included 100 patients with type 2 diabetes.
- Trial name
- LIRAFLAME (NCT03449654)
- Testing
- Liraglutide
- Where
- Denmark
- Volunteers
- 102 people
- Sponsor
- Steno Diabetes Center Copenhagen
Metabolism and Nutrition Disorder, Obesity
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea
This trial is conducted in North America. The aim of the trial is to investigate the effect of liraglutide in obese subjects with sleep apnoea.
- Conditions
- Metabolism and Nutrition Disorder, Obesity, Obstructive Sleep Apnoea
- Trial name
- NCT01557166
- Testing
- liraglutide
- Where
- 42 sites in United States, Canada
- Volunteers
- 359 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Cardiovascular Diseases
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
The primary purpose of study is to estimate the incidence and comparative effect on health outcomes: 1) hospitalization for heart failure, 2) below knee lower extremity amputation.
- Trial name
- NCT03492580
- Testing
- Canagliflozin, Empagliflozin, Dapagliflozin
- Where
- United States
- Volunteers
- 714,582 people
- Sponsor
- Janssen Research & Development, LLC
Osteoarthritis, Obesity
Ultrasound Assessment of the Carotid Intimal Medial Thickness in Obese Subjects; Weight Loss
This is a substudy to a randomised trial investigating the effect of liraglutide on body weight and pain in overweight or obese patients with knee osteoarthritis (NCT02905864).
- Trial name
- CIMT-LOSEIT-I (NCT02954627)
- Testing
- Dietary Supplement: Intensive dietary intervention
- Where
- Denmark
- Volunteers
- 200 people
- Sponsor
- Henrik Gudbergsen
Diabetes, Diabetes Mellitus, Type 2
Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes
This study is conducted in Europe. The aim of the study is to compare the effect of semaglutide subcutaneous (s.c., under the skin) 1.0 mg once-weekly to liraglutide s.c.1.2 mg once-daily on blood sugar levels after 30 weeks of…
- Trial name
- SUSTAIN 10 (NCT03191396)
- Testing
- Semaglutide, Liraglutide
- Where
- 92 sites in Bulgaria, Czechia and 10 more
- Volunteers
- 577 people
- Sponsor
- Novo Nordisk A/S
Prediabetes, Type 2 Diabetes
RISE Adult Medication Study
The RISE Adult Medication Study is a 4-arm, 3-center, clinical trial of adults with prediabetes and early type 2 diabetes to address the hypothesis that aggressive glucose lowering will lead to recovery of beta-cell function that…
- Trial name
- RISE Adult (NCT01779362)
- Testing
- Metformin, Liraglutide, Glargine
- Where
- 4 sites in United States
- Volunteers
- 267 people, healthy volunteers welcome
- Sponsor
- RISE Study Group
Atrial Fibrillation, Recurrence
Outcome of Overweight AF Patients Following Ablation With a Potential Weight Loss Medication ( GOAL-AF )
Atrial Fibrillation (AF) is the most common abnormal heart rhythm(arrhythmia) affecting about one in 40 people in England. Patients with AF often have symptoms ranging from palpitations and breathlessness, and a small number of…
- Conditions
- Atrial Fibrillation, Recurrence, Overweight and Obesity, Liraglutide
- Trial name
- GOAL-AF (NCT05221229)
- Testing
- Liraglutide plus upstream risk factors modification advice and consultation
- Where
- United Kingdom
- Volunteers
- 29 people
- Sponsor
- University Hospital Birmingham
Healthy, Growth Hormone Deficiency
Effects of GH and Lirglutide on AgRP
This is a randomized, placebo-controlled, cross-over study with 4 arms. Healthy and GH deficient adults ages 18-45 years will be studied. Arms will consist of 21-day treatment periods and be separated by 8-week washout periods.
- Trial name
- NCT05681299
- Testing
- growth hormone and lirglutide, growth hormone, liraglutide
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Columbia University
Type 2 Diabetes, Obesity
The Microvascular Function of GLP-1 and Its Analogues
Incretins have become a successful drug target in the repertoire of medications used for the treatment of type 2 diabetes. However little is known about a potential benefit of GLP-1 on the vascular system in humans, independent…
- Trial name
- NCT01677104
- Testing
- GLP-1
- Where
- United Kingdom
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Katarina Kos
Type 1 Diabetes Mellitus
Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes
This is a single center, prospective, randomized, double blinded placebo controlled study conducted I patients with type 1 diabetes.The aim of this study is to examine the additive effects of GLP-1 agonist and SGLT2 inhibitor in…
- Trial name
- NCT02518945
- Testing
- Dapagliflozin, Insulin, Liraglutide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University at Buffalo
HIV Infection, Diabetes Mellitus Type 2
Liraglutide for HIV-associated Neurocognitive Disorder
This study will test the effect of liraglutide on cognitive function in HIV-infected overweight or obese subjects with type 2 diabetes.
- Conditions
- HIV Infection, Diabetes Mellitus Type 2, Obesity, Overweight
- Trial name
- NCT02743598
- Testing
- Liraglutide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Temple University
Type 2 Diabetes, Cardiovascular Diseases
Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease
In an unbiased metabolomics approach with subsequent pathway analyses, the current study seeks to examine the effect of Liraglutide treatment on the metabolic signature in treated patients as well as the effect of Liraglutide on…
- Trial name
- Lirabolic (NCT04057261)
- Testing
- Liraglutide Pen Injector [Victoza]
- Where
- Germany
- Sponsor
- RWTH Aachen University
Obesity, HIV Infections
LIROH - Liraglutide for Obesity in HIV
The goal of this single-arm, open label pilot study is to evaluate liraglutide at the recommended dosage administered subcutaneously + lifestyle counselling for the management of people living with HIV (PLWH) with obesity defined…
- Trial name
- LIROH (NCT06438146)
- Testing
- Liraglutide
- Where
- South Africa
- Volunteers
- 40 people
- Sponsor
- Brigham and Women's Hospital
Obesity, Obesity, Morbid
Liraglutide for Low-responders After Bariatric Surgery
To study the effect of Liraglutide (3.0 mg daily) on 9-month weight loss in low responders 3-months after bariatric surgery.
- Trial name
- LIBAR (NCT04643301)
- Testing
- Liraglutide Pen Injector
- Sponsor
- Zuyderland Medisch Centrum
Obesity
Individualized Obesity Pharmacotherapy
The researchers are trying to identify the specific characteristics (phenotypes) that may be useful to help select the right medication for weight loss.
- Trial name
- NCT03374956
- Testing
- Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion
- Where
- United States
- Volunteers
- 193 people
- Sponsor
- Mayo Clinic
Type 2 Diabetes Mellitus
Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial
This study aims to provide essential mechanistic insights into natriuretic and hemodynamic effects of SGLT2i and GLP-1RA agents in T2D patients.
- Trial name
- NATRIURETIC (NCT04535960)
- Testing
- Empagliflozin 25 MG + Liraglutide 1.8 MG, Liraglutide 1.8 MG + Empagliflozin 25 MG
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- University Health Network, Toronto
Obesity, Type 2 Diabetes Mellitus
Effects of Obesity Treatments on Food Preferences and Metabolism
Obesity and Type 2 Diabetes Mellitus are major health problems which are becoming a burden both for patients and health systems alike.
- Trial name
- FPS (NCT01724060)
- Where
- 2 sites in United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Obesity, Visceral, Cardiovascular Diseases
Impact of Liraglutide 3.0 on Body Fat Distribution
This study is a clinical study to investigate the efficacy of liraglutide compared to placebo in reducing visceral adiposity measured by MRI in overweight or obese subjects at high risk for cardiovascular disease after 40 weeks…
- Conditions
- Obesity, Visceral, Cardiovascular Diseases, Fat Disorder
- Trial name
- NCT03038620
- Testing
- Liraglutide
- Where
- United States
- Volunteers
- 235 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center